Solid Biosciences Inc. (SLDB) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
SLDB currently has 98.4M outstanding shares. with significant dilution risk as 63.4M authorized shares could dilute existing holders by 64.4%. The company has significantly diluted shareholders by 228.4% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 12, 2026 |
10-Q filing | 98.4M shares outstanding |
98M | 63M |
| Mar 19, 2026 |
S-3 filing: This prospectus relates to the resale from time to time of up to 42,780,739 shares of common stock of Solid Biosciences Inc. by the selling stockholders. |
78M | 84M |
| Mar 19, 2026 |
S-3 filing: This S-3 filing relates to the resale of 1,316,899 shares of common stock of Solid Biosciences Inc. by FA212 LLC, acquired in a private placement on January 15, 2026. |
78M | 41M |
| Mar 19, 2026 |
10-K filing | 98.4M shares outstanding |
98M | 19M |
| Nov 03, 2025 |
10-Q filing | 77.9M shares outstanding |
78M | 40M |
| Aug 12, 2025 |
10-Q filing | 77.9M shares outstanding |
78M | 40M |
| May 15, 2025 |
10-Q filing | 77.5M shares outstanding |
78M | 40M |
| May 15, 2025 |
S-3 filing: The company is filing an S-3 to register the offer and sale of debt securities, common stock, preferred stock and depositary shares, up to an aggregate offering price of $400,000,000. |
77M | 40M |
| Mar 06, 2025 |
S-3 filing: Solid Biosciences Inc. is registering 975,496 shares of common stock on behalf of the selling stockholder, FA212 LLC, for resale from time to time. |
41M | 83M |
| Mar 06, 2025 |
S-3 filing: This prospectus relates to the resale from time to time of up to 364,990 shares of common stock of Solid Biosciences Inc. by Mayo Foundation for Medical Education and Research. |
41M | 83M |
| Mar 06, 2025 |
10-K filing | 77.5M shares outstanding |
77M | 47M |
| Nov 06, 2024 |
10-Q filing | 41.4M shares outstanding |
41M | 82M |
| Aug 13, 2024 |
10-Q filing | 40.9M shares outstanding |
41M | 82M |
| May 15, 2024 |
10-Q filing | 38.2M shares outstanding |
38M | 85M |
| May 15, 2024 |
S-3/A filing: The company may offer and sell securities from time to time in one or more offerings of up to $300,000,000 in aggregate offering price. |
38M | 85M |
| Mar 13, 2024 |
S-3 filing: The company intends to offer and sell securities from time to time in one or more offerings of up to $300,000,000 in aggregate offering price, including common stock offered at an aggregate price of up to $75,000,000. |
37M | 86M |
| Mar 13, 2024 |
10-K filing | 37.8M shares outstanding |
38M | 85M |
| Jan 30, 2024 |
S-3 filing: This prospectus relates to the resale from time to time of up to 19,685,581 shares of common stock of Solid Biosciences Inc. by the selling stockholders listed on page 8, including their transferees, pledgees or donees, or their respective successors-in-interest, which includes 2,712,478 shares of our common stock issuable upon the exercise of pre-funded warrants to purchase shares of our common stock, issued to the selling stockholders in our January 2024 private placement. |
20M | 96M |
| Nov 08, 2023 |
10-Q filing | 20.1M shares outstanding |
20M | 77M |
| Aug 14, 2023 |
10-Q filing | 19.7M shares outstanding |
20M | 77M |
| May 11, 2023 |
10-Q filing | 19.6M shares outstanding |
20M | 77M |
| Mar 23, 2023 |
10-K filing | 19.6M shares outstanding |
20M | 77M |
| Jan 26, 2023 |
S-3 filing: This prospectus relates to the resale from time to time of up to 11,992,548 shares of common stock of Solid Biosciences Inc. by the selling stockholders. |
7.5M | 89M |
| Nov 10, 2022 |
10-Q filing | 7.5M shares outstanding |
7.5M | 77M |
| Aug 11, 2022 |
10-Q filing | 112.9M shares outstanding |
110M | 0 |
| Apr 27, 2022 |
10-Q filing | 112.8M shares outstanding |
110M | 0 |
| Mar 14, 2022 |
10-K filing | 110.5M shares outstanding |
110M | 0 |
| Nov 03, 2021 |
10-Q filing | 110.3M shares outstanding |
110M | 0 |
| Aug 16, 2021 |
S-3 filing: The company is filing an S-3 to register the offer and sale of up to $75,000,000 of its common stock through Jefferies, acting as its sales agent and an additional $200,000,000 in aggregate offering price of debt securities, common stock, preferred stock and depositary shares. |
110M | 0 |
| Aug 16, 2021 |
10-Q filing | 110.3M shares outstanding |
110M | 0 |
| May 14, 2021 |
10-Q filing | 110.3M shares outstanding |
110M | 0 |
| Mar 15, 2021 |
10-K filing | 85.1M shares outstanding |
85M | 0 |
| Mar 15, 2021 |
S-3 filing: Solid Biosciences Inc. is filing an S-3 prospectus to register 24,324,320 shares of common stock for resale by selling stockholders who received these shares in a December 2020 private placement. |
60M | 24M |
| Nov 05, 2020 |
10-Q filing | 60.4M shares outstanding |
60M | 0 |
| Aug 06, 2020 |
10-Q filing | 46.1M shares outstanding |
46M | 0 |
| May 07, 2020 |
10-Q filing | 46.1M shares outstanding |
46M | 0 |
| Mar 12, 2020 |
10-K filing | 46.1M shares outstanding |
46M | 0 |